Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target

Yiping Wen; Jing Cai; Yaya Hou; Zaiju Huang; Zehua Wang

doi:10.18632/oncotarget.16467

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target

Yiping Wen _, Jing Cai, Yaya Hou, Zaiju Huang and Zehua Wang

PDF | HTML | How to cite

Oncotarget. 2017; 8:37974-37990. https://doi.org/10.18632/oncotarget.16467

Metrics: PDF 3238 views | HTML 7532 views | ?

Abstract

Yiping Wen1,*, Jing Cai1,*, Yaya Hou1, Zaiju Huang1 and Zehua Wang1

1 Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

* These authors have contributed equally to this work

Correspondence to:

Zehua Wang, email:

Keywords: EZH2, cancer stem cells, sphere, histone lysine methylation, polycomb repressive complex

Received: November 02, 2016 Accepted: March 02, 2017 Published: March 22, 2017

Abstract

Epigenetic modifications in cancer stem cells largely result in phenotypic and functional heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly expressed in cancer stem cells of numerous malignant tumors and has a critical function in cancer stem cell expansion and maintenance. Here, we review up-to-date information regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem cells in various malignant tumors and discuss the therapeutic potential of targeting EZH2 in tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16467

Publication Alerts

Post-Publication Promotion

Reviews:

Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target

Abstract